您当前的位置：
首页 >
文章列表页 >
Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer
更新时间：2026-07-16

    • Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer

    • ZHONGGUO YAOFANG   Vol. 37, Issue 7, Pages: 920-926(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.07.16    

      CLC： R956;R735.2

    • Received：12 January 2026，

      Revised：2026-03-16，

      Accepted：16 March 2026，

      Published：15 April 2026

    移动端阅览

  • HUANG Ying,LI Su,WANG Yan,et al.Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer[J].ZHONGGUO YAOFANG,2026,37(07):920-926. DOI： 10.6039/j.issn.1001-0408.2026.07.16.

  •  
  •  

0

Views

135

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

阿仑膦酸钠预防绝经后妇女骨质疏松性骨折的成本-效用分析
伊伐布雷定治疗我国慢性心力衰竭患者的成本-效用分析
我国应用阿司匹林进行心血管疾病一级预防的药物经济学评价
Cost-utility analysis of durvalumab for consolidation therapy after chemoradiotherapy for stage Ⅲ non-small cell lung cancer
Cost-utility Analysis of Atezolizumab Combined with Standard Chemotherapy Regimen in the First-line Treatment of Extensive-stage Small-cell Lung Cancer

Related Author

FENG Xin
GAO Ying
PAN Xuemei
MAO Jiajia
FANG Demin
FU Jie
WU Bin
LIN Houwen

Related Institution

Dept. of Pharmacy， Xi’an Chest Hospital
Dept. of Pharmacy， The First Affiliated Hospital of Xi’an Jiaotong University
School of International Pharmaceutical Business，China Pharmaceutical University
Research Center for Pharmacoeconomics Evaluation， China Pharmaceutical University
Dept. of Pharmacy， Hebei Medical University Third Hospital
0